086900 — Medy Tox Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapFalling Star

Market Cap
KR₩803bn
Enterprise Value
KR₩822bn
Revenue
KR₩229bn

Annual income statement for Medy Tox, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	140,828	184,870	195,096	221,121	228,622
Cost of Revenue
Gross Profit	74,341	105,853	126,405	133,871	139,029
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	182,279	54,520	154,250	196,864	209,801
Operating Profit	-41,452	130,349	40,846	24,257	18,821
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-42,139	128,265	49,526	15,853	17,499
Provision for Income Taxes
Net Income After Taxes	-30,039	93,263	36,596	9,690	16,074
Minority Interest
Net Income Before Extraordinary Items
Net Income	-29,577	94,154	37,010	9,755	16,955
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-29,577	93,179	36,035	8,780	15,980
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-4,172	3,825	6,170	739	2,541
Dividends per Share